Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-04-07 Sale |
2025-04-09 4:25 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $18.04 | $120,269 | 316,643 (Indirect) |
View |
| 2025-03-27 Sale |
2025-03-31 7:37 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $21.33 | $69,321 | 151,556 (Direct) |
View |
| 2025-03-24 Sale |
2025-03-26 7:37 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $22.5 | $22,505 | 154,806 (Direct) |
View |
| 2025-03-19 Sale |
2025-03-21 5:49 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,500 | $20.61 | $257,575 | 1,002,688 (Indirect) |
View |
| 2025-03-17 Sale |
2025-03-19 5:42 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,500 | $20.83 | $260,320 | 990,392 (Indirect) |
View |
| 2025-03-07 Sale |
2025-03-11 5:18 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $21.44 | $142,936 | 323,310 (Indirect) |
View |
| 2025-02-27 Sale |
2025-03-03 8:07 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $20.41 | $66,327 | 155,806 (Direct) |
View |
| 2025-02-07 Sale |
2025-02-10 5:32 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
6,667 | $21.93 | $146,206 | 500,977 (Indirect Direct) |
View |
| 2025-02-05 Sale |
2025-02-07 7:06 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $22.52 | $22,524 | 159,056 (Direct) |
View |
| 2025-01-27 Sale |
2025-01-29 7:21 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $21.59 | $70,178 | 160,056 (Direct) |
View |
| 2025-01-07 Sale |
2025-01-10 5:31 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
28,367 | $24.18 | $685,868 | 381,880 (Indirect Direct) |
View |
| 2025-01-03 Sale |
2025-01-07 4:43 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $25.04 | $25,039 | 318,862 (Direct) |
View |
| 2024-12-27 Sale |
2024-12-31 5:18 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $22.23 | $94,474 | 329,512 (Direct) |
View |
| 2024-11-27 Sale |
2024-12-02 5:18 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $24.89 | $130,688 | 168,556 (Direct) |
View |
| 2024-10-28 Sale |
2024-10-30 6:04 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $28.56 | $178,485 | 173,806 (Direct) |
View |
| 2024-10-18 Sale |
2024-10-22 4:23 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
716 | $30 | $21,483 | 343,311 (Indirect) |
View |
| 2024-10-18 Sale |
2024-10-22 4:22 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
847 | $30 | $25,413 | 1,015,188 (Indirect) |
View |
| 2024-10-18 Sale |
2024-10-22 4:21 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
924 | $30 | $27,723 | 1,002,892 (Indirect) |
View |
| 2024-10-18 Sale |
2024-10-22 4:19 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
814 | $30 | $24,422 | 180,056 (Direct) |
View |
| 2024-10-18 Sale |
2024-10-22 4:18 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,570 | $30 | $47,104 | 188,245 (Indirect Direct) |
View |
| 2024-10-18 Sale |
2024-10-22 4:17 pm |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
816 | $30 | $24,482 | 266,268 (Direct) |
View |
| 2024-10-15 Sale |
2024-10-17 5:06 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $27.67 | $35,143 | 189,815 (Indirect Direct) |
View |
| 2024-10-08 Sale |
2024-10-10 8:39 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
51,145 | $28.11 | $1,437,585 | 1,016,035 (Indirect) |
View |
| 2024-10-08 Sale |
2024-10-10 8:38 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
29,977 | $28.07 | $841,334 | 1,003,816 (Indirect) |
View |
| 2024-10-08 Sale |
2024-10-10 8:36 pm |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
10,420 | $28.17 | $293,557 | 104,091 (Direct) |
View |
| 2024-10-04 Sale |
2024-10-08 6:58 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
10,229 | $27.54 | $281,664 | 1,067,180 (Indirect) |
View |
| 2024-10-04 Sale |
2024-10-08 6:57 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
14,936 | $27.51 | $410,867 | 1,033,793 (Indirect) |
View |
| 2024-10-04 Sale |
2024-10-08 6:56 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
11,488 | $27.51 | $316,014 | 363,010 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-27 Exercise |
2025-03-31 7:37 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 151,556 (Direct) |
View |
| 2025-03-27 Exercise |
2025-03-31 7:37 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 151,556 (Direct) |
View |
| 2025-03-24 Exercise |
2025-03-26 7:37 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $0 | 154,806 (Direct) |
View |
| 2025-03-24 Exercise |
2025-03-26 7:37 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $2.48 | 154,806 (Direct) |
View |
| 2025-03-04 Exercise |
2025-03-06 6:02 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
10,000 | $0 | 155,806 (Direct) |
View |
| 2025-03-04 Exercise |
2025-03-06 6:02 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
10,000 | $2.48 | 155,806 (Direct) |
View |
| 2025-02-27 Exercise |
2025-03-03 8:07 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 155,806 (Direct) |
View |
| 2025-02-27 Exercise |
2025-03-03 8:07 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 155,806 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:40 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:39 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Kunkel Lori Anne Director |
15,368 | $0 | 15,368 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:38 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
23,014 | $0 | 23,014 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:36 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:35 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:34 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:33 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
20,491 | $0 | 20,491 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:32 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
171,000 | $0 | 500,977 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:29 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
171,000 | $0 | 171,000 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:28 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
490,000 | $0 | 490,000 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:27 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
171,000 | $0 | 171,000 (Direct) |
View |
| 2025-02-06 Option Award |
2025-02-10 5:25 pm |
N/A 2035-02-06 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
171,000 | $0 | 171,000 (Direct) |
View |
| 2025-02-05 Exercise |
2025-02-07 7:06 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $0 | 159,056 (Direct) |
View |
| 2025-02-05 Exercise |
2025-02-07 7:06 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $2.48 | 159,056 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 7:21 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 160,056 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 7:21 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 160,056 (Direct) |
View |
| 2025-01-07 Exercise |
2025-01-10 5:31 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
21,700 | $0 | 381,880 (Direct) |
View |
| 2025-01-07 Exercise |
2025-01-10 5:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
11,000 | $2.48 | 381,880 (Direct) |
View |
| 2025-01-07 Exercise |
2025-01-10 5:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
10,700 | $1.12 | 381,880 (Direct) |
View |
| 2024-12-13 Exercise |
2025-01-07 4:43 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
14,000 | $0 | 318,862 (Direct) |
View |
| 2024-12-13 Exercise |
2025-01-07 4:43 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
14,000 | $2.48 | 318,862 (Direct) |
View |
| 2024-12-27 Exercise |
2024-12-31 5:18 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $0 | 329,512 (Direct) |
View |
| 2024-12-27 Exercise |
2024-12-31 5:18 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $2.48 | 329,512 (Direct) |
View |
| 2024-11-27 Exercise |
2024-12-02 5:18 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $0 | 168,556 (Direct) |
View |
| 2024-11-27 Exercise |
2024-12-02 5:18 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $2.48 | 168,556 (Direct) |
View |
| 2024-10-28 Exercise |
2024-10-30 6:04 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $0 | 173,806 (Direct) |
View |
| 2024-10-28 Exercise |
2024-10-30 6:04 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $2.48 | 173,806 (Direct) |
View |
| 2024-10-18 Exercise |
2024-10-22 4:19 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
814 | $0 | 180,056 (Direct) |
View |
| 2024-10-18 Exercise |
2024-10-22 4:19 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
814 | $2.48 | 180,056 (Direct) |
View |
| 2024-10-18 Exercise |
2024-10-22 4:17 pm |
N/A 2031-06-17 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
816 | $0 | 266,268 (Direct) |
View |
| 2024-10-18 Exercise |
2024-10-22 4:17 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise CHIEF MEDICAL OFFICER |
816 | $2.48 | 266,268 (Direct) |
View |
| 2024-10-08 Exercise |
2024-10-10 8:36 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
4,106 | $5.52 | 104,091 (Direct) |
View |
| 2024-10-08 Exercise |
2024-10-10 8:36 pm |
N/A 2029-05-16 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
10,420 | $0 | 104,091 (Direct) |
View |
| 2024-10-08 Exercise |
2024-10-10 8:36 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
6,314 | $19.68 | 104,091 (Direct) |
View |
| 2024-10-04 Exercise |
2024-10-08 6:56 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
11,488 | $0 | 363,010 (Direct) |
View |
| 2024-10-04 Exercise |
2024-10-08 6:56 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
11,488 | $2.48 | 363,010 (Direct) |
View |